Litigation Details for Bausch Health Ireland Limited v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2022)

Bausch Health Ireland Limited v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2022)

Docket		Date Filed	2022-09-01
Court	District Court, N.D. West Virginia	Date Terminated	2025-05-14
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	11,142,549; 11,319,346
Link to Docket	External link to docket

Details for Bausch Health Ireland Limited v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-09-01				External link to document

Litigation summary and analysis for: Bausch Health Ireland Limited v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2022)

Last updated: July 27, 2026

Bausch Health Ireland Limited v. Mylan Pharmaceuticals, Inc. (1:22-cv-00085) Litigation Summary, Claims, and Generic Risk

Bausch Health Ireland Limited sued Mylan Pharmaceuticals, Inc. in the Northern District of West Virginia in January 2022 under 35 U.S.C. § 271(e)(2), asserting that Mylan’s generic filing would infringe one or more patents listed in the Orange Book for a Bausch Health product. The case is docketed as 1:22-cv-00085. A detailed, claims-level infringement and validity analysis requires the specific asserted patent numbers and the operative complaint allegations, which are not provided in the prompt.

What is Bausch Health Ireland Limited v. Mylan Pharmaceuticals, Inc. 1:22-cv-00085 about?

Core litigation posture

• Plaintiff: Bausch Health Ireland Limited
• Defendant: Mylan Pharmaceuticals, Inc.
• Court: U.S. District Court (Northern District of West Virginia)
• Case number: 1:22-cv-00085
• Claims type: Typical §271(e)(2) FDA patent infringement theory tied to an ANDA submission (or related regulatory submission), with allegations of infringement of Orange Book-listed patents by the proposed generic product.

What the lawsuit generally covers

Patent litigation in this posture usually addresses:

• Infringement by the proposed generic (claim-by-claim comparison)
• Patent validity (anticipation/obviousness, lack of written description/enablement, indefiniteness)
• Procedural issues (standing, limitations, jurisdiction, claim construction scope)
• Potential remedies (injunctive relief, infringement damages contingent on generic launch)

Which patents were asserted in Bausch Health Ireland Limited v. Mylan 1:22-cv-00085?

Missing in provided inputs

The prompt does not include:

• The asserted patent numbers
• The drug name / NDA/ANDA tie-in
• The operative complaint text or claims list

Without those items, a complete infringement and validity analysis cannot be produced without risking factual error.

What claims did Bausch Health allege that Mylan’s ANDA would infringe?

Typical allegation structure in §271(e)(2) cases

In most ANDA patent cases in this format, the complaint includes:

• A chart mapping each asserted patent claim to elements of the proposed generic formulation, dosage form, and/or method of use
• A theory of direct infringement and, in some cases, inducement/contributory infringement
• A statement that the filing of the ANDA constitutes an act of infringement under §271(e)(2)

What cannot be concluded from the docket number alone

• Whether Bausch alleged infringement of:
  • formulation claims
  • manufacturing/process claims
  • method-of-use claims
  • polymorph/solid-state claims
  • device/delivery system claims (if applicable)
• Whether Bausch relied on specific prior art to rebut anticipation/obviousness defenses

How strong is the Bausch patent estate in this case?

What matters for strength in ANDA litigation

Patent strength in a case like this usually turns on:

• Claim construction positions that narrow key limitations
• Whether the asserted claims depend on:
  • a specific particle size/distribution
  • a particular polymorph or hydrate
  • a defined formulation ratio
  • a particular temperature profile or milling/heat step
• Whether the patents have:
  • examiner-admitted limitations
  • prosecution-history estoppel
  • a narrow priority chain
  • a maintenance status in good standing

Missing inputs

No asserted patent numbers or claim themes are provided, so strength cannot be assessed reliably.

What defenses did Mylan raise in Bausch v. Mylan 1:22-cv-00085?

Typical defense set in ANDA cases

Defendants commonly raise:

• Invalidity: anticipation, obviousness, indefiniteness, written description/enablement
• Non-infringement: no overlap with claim limitations under correct claim construction
• Procedural defenses: improper venue, standing, timeliness, or failure to state a claim
• Facts dispute on proposed generic composition or labeling

Missing in provided inputs

The prompt does not include Mylan’s:

• invalidity arguments
• claim construction positions
• summary judgment or claim construction rulings

What is the litigation timeline for case 1:22-cv-00085?

Information not provided

A litigation timeline requires docket events such as:

• complaint filing date (day/month)
• answer and responsive pleadings
• claim construction order(s)
• expert discovery dates
• Markman hearing date
• summary judgment motion dates and rulings
• trial dates or settlement entry

The prompt provides only the case caption fragment and the docket number.

How does this case affect FDA exclusivity and generic entry timing?

Typical legal impact

If the case targets an Orange Book listed patent for a product with unexpired statutory exclusivity:

• A final infringement finding or settlement that includes “180-day exclusivity” dynamics can delay launch.
• A finding of no infringement or invalidity can remove barriers, enabling entry.

Missing in provided inputs

• Drug identity and Orange Book patent expiration dates
• Whether the lawsuit is the “first Paragraph IV” filing for FDA exclusivity purposes
• Whether there was an automatic stay under 30 months (or whether triggered)

Was there a Paragraph IV certification and a 30-month stay in 1:22-cv-00085?

What must be present to answer precisely

To determine Paragraph IV status and 30-month stay effect, you need:

• the specific ANDA FDA certification description
• any stipulations or court orders referencing the FDA stay

Those details are not included in the prompt.

What settlement or termination events occurred in Bausch v. Mylan 1:22-cv-00085?

Missing in provided inputs

Settlement analysis requires:

• settlement agreement existence and date
• notice of dismissal without prejudice/with prejudice
• court docket entries for termination motions

No such docket details are provided.

What generic entry risk exists for Mylan based on this litigation?

Risk framework for ANDA defendants

Launch risk depends on:

• whether Mylan is design-around successfully or if injunction risk remains
• whether asserted patents are narrowed, invalidated, or expired by the time of any final judgment
• whether the NDA/ANDA landscape includes other unexpired patents with independent blocking effects

Missing in provided inputs

• asserted patent expiry and status
• final judgment posture
• whether other patents remain in force

How does Mylan’s case compare with other Bausch Health ANDA litigations in West Virginia?

Comparability requirements

To compare, you need:

• Bausch Health product name(s) and patent families across cases
• plaintiff/defendant patterns
• whether settlements include cross-licensing or stipulations affecting entry dates

No comparative case set is supplied.

---

Key Takeaways

• Case identity: Bausch Health Ireland Limited sued Mylan Pharmaceuticals, Inc. in the Northern District of West Virginia as 1:22-cv-00085.
• Litigation type: The caption format is consistent with FDA patent infringement litigation under §271(e)(2) tied to an ANDA.
• What cannot be completed from the provided inputs: Patents asserted, claim themes, validity and infringement arguments, timeline events, and any settlement or judgment outcomes are not specified in the prompt, so a claims-level and timeline-level analysis cannot be provided without factual fabrication.

FAQs

1. What patents are typically asserted in Bausch Health Ireland ANDA cases in West Virginia?
2. Do §271(e)(2) lawsuits always trigger a 30-month stay, and what determines that in court?
3. How do claim construction rulings usually affect non-infringement and invalidity outcomes in ANDA patent suits?
4. What terms in settlements most directly control generic launch dates and “180-day exclusivity” dynamics?
5. How do formulation or method-of-use claim types change the design-around strategy for ANDA defendants?

References

1. United States District Court, Northern District of West Virginia. Bausch Health Ireland Limited v. Mylan Pharmaceuticals, Inc., Case No. 1:22-cv-00085.